Comparison of the cancer cell-killing effect of the DOS scheme and the SOX scheme for neoadjuvant chemotherapy for gastric cancer

• Main Authors: Ya-Ni Chen, Hai-Feng HU
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2017-07-01
• Series: Journal of Hainan Medical University
• Subjects: Gastric cancer; Neoadjuvant chemotherapy; Proliferation; Cell cycle; Invasion
• Online Access: http://www.hnykdxxb.com/PDF/201713/30.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To study the cancer cell-killing effect of the DOS scheme and the SOX scheme for neoadjuvant chemotherapy for gastric cancer. Methods: A total of 76 patients with gastric cancer who underwent preoperative neoadjuvant chemotherapy in Ansai People’s Hospital between June 2014 and October 2016 were selected and randomly divided into the SOX group who received oxaliplatin + S-1 scheme chemotherapy and the DOS group who accepted oxaliplatin + S-1 + docetaxel scheme chemotherapy. Serum tumor marker levels were measured before and after the chemotherapy, and the expression of proliferation genes, tumor suppressor genes and invasion genes in lesions were determined after chemotherapy. Results: Serum CA72-4, G17 and TK-1 levels of both groups of patients after chemotherapy were significantly lower than those before chemotherapy and serum CA72-4, G17 and TK-1 levels of DOS group after chemotherapy were significantly lower than those of SOX group; after chemotherapy, CyclinB, CyclinD1, CDK1, CDK4, CDK6, Vav2, MMP2, ADAM8 and ITF2 mRNA expression in surgically removed lesions of DOS group were significantly lower than those of SOX group while RASSF1A, Noxa, GKN1 and p16ink4a mRNA expression were significantly higher than those of SOX group. Conclusion: DOS neoadjuvant chemotherapy can be more effective than SOX in killing the gastric cancer cells and inhibiting the proliferation and invasion of cancer cells.